Baby Bunting share price: is the stock a buy?

We unpack Baby Bunting's latest H1 results as well as look at what one top broker is currently saying about the stock.

Touting strong growth in a niche space, Baby Bunting (ASX: BBN) – a self-described one stop baby shop – has seen its share price rise more than 60% in the last 12-months.

Baby Bunting share price: interim results in focus

The release of the company’s interim results last week gave investors insight into how the company performed during the last six months of CY20 – and maybe most importantly: whether or not that ~60% run-up was justified.

Indeed, though the market first responded negatively – with the stock being bid down more than 10% following the H1 release – the share price has since stabilised.

Do you own Baby Bunting shares? You can hedge your downside risk by trading CFDs now.

Looking at these results, on the top-line, the company reported sales of $186.4 million – representing 8% growth on a pcp basis.

On the bottom-line, the company reported pro forma earnings (EBITDA) of $14.3 million (+21% on a pcp basis) and profits (NPAT) of $4.8 million. Margins also improved during the half, with gross profit margins hitting 36.9%.

The company further expects FY20 gross margins to come in even stronger: at 37.0%.

This margin outlook, said the company 'is an outcome of working with our supplier partners on range improvements, further improvements in trading terms, optimising supply chain opportunities and increases in direct import volumes.'

One key negative that stood out however as part of these results was commentary surrounding the potential impact of the Coronavirus.

Here it was noted that because 'Baby Bunting sources products, either directly or through distributors, from China. The effect on Baby Bunting arising from the coronavirus outbreak in China cannot yet be readily determined.'

The company did however reassure investor thats it had ‘sufficient’ stock on hand – suggesting there would be no inventory short-falls just yet.

The analyst view

In response to the H1, Citi reiterated their 'buy' rating and upgraded their share price target to $4.05 from $3.90 on BBN.

With Baby Bunting (ASX: BBN) currently trading at $3.58 per share, that price target would imply upside of ~13%.

The investment bank expects Baby Bunting to report FY20 sales of 403.5 million against earnings (Core NPAT) of $21.0 million.

However Citi analysts did flag that their NPAT guidance 'does not account for coronavirus disruption.'

'That said we see Baby Bunting as less exposed to this risk compared to other retailers given the company's elevated stock position following weaker than expected 1H20 sales combined with the fact that its suppliers also hold stock in Australia,’ Citi analysts also said.

Of the four brokers covering the stock, all of them rate Baby Bunting a ‘buy’, according to Bloomberg Data.

Practise trading Australian stocks with an IG demo account now.

IGA, may distribute information/research produced by its respective foreign affiliates within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.

The information/research herein is prepared by IG Asia Pte Ltd (IGA) and its foreign affiliated companies (collectively known as the IG Group) and is intended for general circulation only. It does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. You should take into account your specific investment objectives, financial situation, and particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit.

Please see important Research Disclaimer.

Seize a share opportunity today

Go long or short on thousands of international stocks.

  • Increase your market exposure with leverage
  • Get spreads from just 0.1% on major global shares
  • Trade CFDs straight into order books with direct market access

Live prices on most popular markets

  • Forex
  • Shares
  • Indices
liveprices.javascriptrequired
liveprices.javascriptrequired

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.

liveprices.javascriptrequired

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 20 mins.

The Momentum Report

Get the week’s momentum report sent directly to your inbox every Monday for FREE. The Week Ahead gives you a full calendar of upcoming key events to monitor in the coming week, as well as commentary and insight from our expert analysts on the major indices to watch.

For more info on how we might use your data, see our privacy notice and access policy and privacy webpage.

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.